Evaluating the role of β-nicotyrine in e-cigarette addiction
Official title: An evaluation of Beta-nicotyrine as a potential contributor to the abuse liability of e-cigarettes
Funded at Hennepin Healthcare Research Institute · NIH-10689116 · Data updated 2026-11-12
This study is looking at how a substance called β-nicotyrine, found in e-cigarettes, might affect nicotine addiction, helping us understand the risks of using e-cigarettes better for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hennepin Healthcare Research Institute NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | September 15, 2021 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $330,726 |
| NIH project number | 5R01DA053608-03 |
| Project ID | NIH-10689116 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who use e-cigarettes and may be at risk for nicotine addiction.
✕Less likely to help
Patients who do not use e-cigarettes or are not at risk for nicotine addiction may not benefit from this research.
What this research studies
This research investigates how β-nicotyrine, a minor alkaloid found in e-cigarettes, may influence nicotine addiction. The study will analyze the pharmacokinetics of β-nicotyrine, including how it interacts with nicotinic receptors in the body. By understanding its effects on nicotine metabolism and addiction potential, the research aims to provide insights that could inform regulatory decisions regarding e-cigarette products. Patients may benefit from a better understanding of the risks associated with e-cigarette use.
Why it matters
Potential benefit: If successful, this research could lead to improved regulations on e-cigarettes, potentially reducing addiction rates among users.
How similar studies have gone: Previous research has shown that understanding the pharmacokinetics of nicotine and its metabolites can lead to significant insights into addiction, suggesting this approach has potential for success.
Where this research is happening
-
Hennepin Healthcare Research Institute
Minneapolis, United States Active
Researchers
- Principal investigator: Smethells, John Richard — Hennepin Healthcare Research Institute
- Study coordinator: Smethells, John Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.